Theodore T. Sand, Ph.D. recently joined the company to support on-going commercialization efforts, as well as initiate an active research program to advance the company’s technology platform by leveraging his 14-years of experience in translational cell therapy. Ted will help to establish a set of services that the company will offer to potential clients that will assist them in utilizing the clinical data they will generate on each patient. He also will monitor developments in the regulation of cell-based therapies. Ted previously was VP of Cellular Therapies & Regulatory Affairs at Celling Biosciences (Austin, Texas). He started his efforts in translational cell therapy in 2002 when he created, optimized and validated the fat tissue-derived stem cell therapy service offered by Vet-Stem, Inc. (Poway, CA).
Dr. Sand received both his B.S. (Microbiology, 1975) and Ph.D. (Biochemistry, 1982) degrees from the University of Minnesota (Minneapolis, MN) and was a Postdoctoral Fellow in the Department of Immunology at Scripps Clinic and Research Foundation (La Jolla, CA) from 1982 to 1983.
Ted has been the inventor or co-inventor on 14 patents, has coauthored 13 scientific publications and wrote posts covering scientific, clinical and regulatory aspects of translational cell therapy for a blog on the Celling Biosciences website. He will continue this effort on the Greyledge Technologies website.